Article
Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2014
Schwab Richard, Petak Istvan, Kollar Mihaly, Pinter Ferenc, Varkondi Edit, Kohanka Andrea, Barti-Juhasz Helga, Schönleber Julia, Brauswetter Diana, Kopper Laszlo, Urban Laszlo
Abstract excerpt
The initial radiotherapy of a 73 years old Caucasian male patient with advanced squamous cell lung carcinoma was terminated due to severe pericarditis. Subsequently, the tumor sample was analyzed for possible targets with comprehensive molecular diagnostics. EGFR, KRAS and PIK3CA genes were wild type, ALK and ROS1 were negative for rearrangement, but c-MET was amplified by fluorescent in situ hybridization. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.